Widespread development of anti-drug antibodies in studies of BioMarin Pharmaceutical Inc.’s Vimizim sparked debate about the role that tolerance induction therapy should play when FDA is making risk-benefit calculations about products where immunogenicity is a significant factor, FDA review documents show.
The effect of neutralizing antibodies on the long-term efficacy and safety of enzyme replacement therapies is a challenging issue for...